Companies

The objective of the OneMedForum is to showcase the most promising private and micro-cap companies actively seeking capital or partnering opportunities. OneMedPlace thanks its network of advisors for assisting us to identify and invite companies with great potential.

OneMedForum NY 2011 Presenting Companies
CompanyDescriptionRecent News


Accord Biosciences
(Private)
[Private Biotech/Device]
Accord Biosciences is developing sensor systems to measure nitric oxide (NO) and its carrier species in blood and other complex samples for clinical diagnostic and research applications.
Accord Biosciences Receives $1.3M NIH SBIR Grant To Develop Pulmonary Hypertension Diagnostic



Adherex Technologies, Inc.
(PNK: AHX.TO)
[Micro-Cap Biotech/Device]
Adherex Technologies Inc. is dedicated to the discovery and development of novel cancer therapeutics. They aim to address important unmet medical needs in cancer. Adherex currently has four products in the clinical stage of development including Exherin and sodium thiosulfate (STS) and Exherin.
Adherex Reports Recent Developments and Fiscal Year Ended December 31, 2010 Financial Results
Commencement of Adherex Rights Offering


ADS Biotechnology, Ltd.
(Private)
[Private Biotech/Device]
ADS Biotechnology, Ltd. is a pre IND biomedical company developing a novel, first-in-class blood volume expander created by scientists at the University of Toledos College of Medicine.
>>> Video Profile
See how ADS-4203 works.


Advanced Cardiac Therapeutics
(Private)
[Private Biotech/Device]
Headquartered in Laguna Beach, California, USA, Advanced Cardiac Therapeutics (ACT) was founded in 2007 to specialize in advanced irrigated cardiac catheter ablation systems with proprietary temperature-sensing technology based on microwave radiometry.
Roy T. Tanaka Joins Board of Directors of Advanced Cardiac Therapeutics

Advanced Cardiac Therapeutics Initiates First-In-Man CE Mark Clinical Trial To Study Innovative Catheter System for the Treatment of Atrial Arrhythmias


ADVENTRX Pharmaceuticals
(NYSE AMEX: ANX)
[Micro-Cap Biotech/Device]
ADVENTRX Pharmaceuticals, Inc. is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use.
>>> Video Profile
ADVENTRX Completes Acquisition of SynthRx
ADVENTRX Reports Fourth Quarter and Full Year 2010 Financial Results


Ascentx Medical
(private: private)
[Micro-Cap Biotech/Device]
Beta Cat Pharmaceuticals, LLC is seeking financial partners for the development of and future sale to a pharmaceutical partner of compounds from its WNT/beta catenin modulator program. Beta Cat successfully acquired the program from Avalon Pharmaceuticals. The lead compound's, BC2059, preclinical data suggests that BC2059 are potent and specific inhibitors of WNT pathway function and specifically promote proteosomal degradation of beta catenin in the cytoplasm, preventing beta catenin from entering the nucleus where it is thought to be a major driver of cancer proliferation.


Beta Cat Pharmaceuticals, LLC
(Private)
[Private Biotech/Device]
Beta Cat Pharmaceuticals, LLC is seeking financial partners for the development of and future sale to a pharmaceutical partner of compounds from its WNT/beta catenin modulator program. Beta Cat successfully acquired the program from Avalon Pharmaceuticals. The lead compound, BC2059, is in late stage preclinical development. Preclinical data suggests that BC2059 and related compounds, and other distinct compound families discovered in this program, are potent and specific inhibitors of WNT pathway function and specifically promote proteosomal degradation of beta catenin in the cytoplasm, preventing beta catenin from entering the nucleus where it is thought to be a major driver of cancer proliferation.


Bio-Path Holdings
(OBB: BPTH.OB)
[Micro-Cap Biotech/Device]
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion.
>>> Video Profile
Zack's Small-Cap Research Release
Bio-Path Holdings Reports Fiscal Year 2010 Operation and Financial Results


Biovista, Inc.
(Private)
[Private Biotech/Device]
Biovista systematically repurposes drugs for unmet medical needs in commercially valuable indications. The company's proprietary discovery platform, termed Clinical Outcome Search Space, utilizes a predictive technology that delineates both drug efficacy and adverse effects. Biovista is currently collaborating with the FDA to predict certain safety outcomes of drugs of interest as well as with Pfizer and Novartis to find new uses for a number of their development stage and marketed drugs.
>>> Video Profile
Biovista to present at the 5th World Generic Medicines Congress
Biovista announces a Webinar on Drug Safety


BMEYE
(Private)
[Private Biotech/Device]
BMEYE develops innovative medical devices with broad application in clinical settings that require cardiovascular monitoring.
>>> Video Profile
BMEYE and PULSION sign Licensing Agreement


Bone Biologics
(Private)
[Private Biotech/Device]
Bone Biologics is an orthobiologics company with a patented platform technology, UCB-1, a recombinant protein that regenerates bone and tissue. The target markets for UCB-1 protein based technologies are bone and cartilage regeneration. The Platform Technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Bone Biologics Announces A Major US Patent Issuance For Its Recombinant Protein Process For The Formation Of Cartilage

Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation


CeQur
(Private)
[Private Biotech/Device]
CeQur is an insulin delivery device company, developing and commercializing a small, discrete, and uniquely simple insulin delivery device for people with type 2 diabetes.
>>> Video Profile
Start Up magazine, January 2010: CeQur makes the "A-List"
Massachusetts Medical Device Journal, January 2010: Q&A with CeQur CEO Jim Peterson


Cerbomed GmbH
(Private)
[Private Biotech/Device]
Cerbomed develops and provides innovative solutions for smart neuro therapies, with a particular focus on people suffering from drug-resistant epilepsy or other difficult-to-treat neurological disorders.
Cerbomed at the INS 10th World Congress
Expanding competences: cerbomed GmbH gains Prof. Dr. Barry R. Komisaruk for its scientific advisory board
Cerbomed appoints new Chairman and expands Advisory Board
Prof. Dr. Christian E. Elger joins the scientific advisory board at cerbomed GmbH
A new study proves the painkilling effect of transcutaneous Vagus Nerve Stimulation at man


Cervilenz Inc
(Private)
[Private Biotech/Device]
Cervilenz Inc. manufactures and markets CerviLenz® – an innovative medical device that measures cervical length to help identify and manage pregnant women at high risk for preterm birth.
About CerviLenz
Clinical Use of CerviLenz
Research on CerviLenz
CerviLenz News & Events


ChromaDex
(OTC BB: CDXC.OB.OB)
[Micro-Cap Biotech/Device]
ChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable “green chemistry” and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards.
>>> Video Profile
"ChromaDex Unveils New Investor Presentation Outlining a Plan for Accelerated Growth
ChromaDex Announces the Launch of BluScience™, a Breakthrough Supplement Line, Nationwide At GNC Stores and On GNC.com
"


Compumedics
(ASX: CMP.ASX)
[Micro-Cap Biotech/Device]
Compumedics' core business is the development and commercialization of technology with a focus on the fast growing Sleep Medicine and Neurology markets. Compumedics is leveraging its existing technology to continue its expansion into a number of related market sectors including cardiac diagnostics, fatigue monitoring, in-depth anesthesia monitoring and sleep disorders therapy.
>>> Video Profile
Compumedics VISTA Client Update :: Issue 30, 2011
World's First Accredited and Paperless Sleep Lab upgrades to Compumedics ProFusion Nexus and High Definition Grael


Del Mar Pharmaceuticals
(Private)
[Private Biotech/Device]
Del Mar Pharmaceuticals' mission is to build shareholder value by rapidly developing and commercializing proven anti-cancer therapies in orphan indications where patients have failed modern biologic therapy.
View Corporate Presentation


DermTech International
(Private)
[Private Biotech/Device]
DermTech is a La Jolla-based biotechnology company developing non-invasive tests to detect disease. Their lead product in development is MelDTect, the first genomic, non-invasive test to detect melanoma. The test has registered 100% sensitivity and 88% specificity in published studies. Based on the current market for skin checks, profit opportunity for this application is estimated ~$900 M annually.
Data on DermTech's Non-invasive Test for Melanoma Are Published in the British Journal of Dermatology - Genomic Test is 100% Sensitive


Direct Flow Medical
(Private)
[Private Biotech/Device]
Direct Flow Medical is a medical device company developing a percutaneous aortic Tissue valve prothesis to provide patients requiring treatment of cardiac valve insufficiently with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.
Direct Flow Medical Announces Key Addition to Management Team and Ninth Patent Issuance


e-Zassi
(Private)
[Private Biotech/Device]
e-Zassi.com is the medical device industry's first subscription-based, integrated online business network, decision support software and technology marketplace. Delivered as a SaaS product, the platform utilizes Web 2.0 tools and cloud computing applications to enhance the development and commercialization of medical devices. e-Zassi.com empowers members through improved decision-making, and increases the potential for success when evaluating new technologies and connecting with potential business partners.
"e-Zassi To Present Solution To Fractured Medical Device Ecosystem
e-Zassi Provides Innovation Empowerment through an Endowment of its InnoVisionTM Software
"


EBS Technologies
(Private)
[Private Biotech/Device]
Electrical Brain Synchronization Technologies (EBS) develops a non-invasive electrical stimulation device for the treatment of functional deficits that result from stroke or brain trauma. The fundamental approach is to produce "electrical brain synchronization (EBS)". The aim is to reduce deficits in the functional domains of language, vision, memory, attention and motor function.
Clinica-medtech Intelligence
3 million EUR investment by Earlybird and Brandenburg Capital


ECI Biotech
(Private)
[Private Biotech/Device]
ECI Biotech, Inc. (ECI) is a premier developer and manufacturer of innovative, patented ExpressDetect sensors for rapid infection determination at the point-of-care (PoC) for professional use, as well as consumer OTC markets.
ECI Biotech to Participate in WPI Alumni Association Community Service Day
ECI Biotech Awarded 2011 Massachusetts Life Sciences Center Accelerator Loan


ENTrigue Surgical
(Private)
[Private Biotech/Device]
ENTrigue Surgical, Inc. is developing next generation medical devices and therapies for surgeries of the Ear, Nose and Throat. They harness proprietary breakthroughs in biotechnology and instrumentation to deliver novel, yet sensible solutions for the ENT operating room and office. The initial focus is on enhancing surgical access for increased functionality and precision.
ENTrigue Surgical, Inc. Announces Initial Clinical Experience with Ventera Sinus Dilation Systems and the Commercial Launch of Synaero Hemostasis Product


EryDel
(Private)
[Private Biotech/Device]
EryDel (acronym of ERYthrocyte DELivery) S.p.A. is a company operating in the pharmaceutical field developing products with a proprietary technology. EryDel is focused on developing and commercializing of innovative therapies and diagnostic tools based on the use of autologous red blood cells as agent carriers, selective drug targeting system, agent passive reservoirs and circulating bioreactors.
EryDel at BIOTECHNICA 2010 in Hannover
EryDel has CE Marked its New Medical Devices for automatic encapsulation of Drugs into Human Autologous Red Blood Cells


GlySure
(Private)
[Private Biotech/Device]
GlySure has developed a continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of Tight Glycemic Control and Intensive Insulin Therapy.
Clinical Trials


Hepregen
(Private)
[Private Biotech/Device]
The mission of Hepregen Corporation is to transform safety assessment and drug development (along the hepatic (or liver) axis) with the commercialization of HepatoPac, a long term, highly functional bio-engineered in vitro micro-liver platform.
Hepregen Corporation Presents Results of Liver Toxicity Study at Annual Meeting of The Society of Toxicoloty. Hepregen's Microliver Platform, HepatoPac™, Provides Increased Confidence in Drug Development to Impact Patient Safety.
Hepregen Corporation Announces Commercial Launch of HepatoPac™ Microliver Platform for In Vitro ADME/Tox Applications.


Histogenics, Inc
(Private)
[Private Biotech/Device]
Histogenics Corporation is a privately held regenerative medicine company that combines a rich portfolio of cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. The Company's flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The NeoCart® cartilage regeneration system is currently enrolling in Phase III IND multicenter, randomized clinical study and the Company was provided a Special Protocol Assessment by the FDA. In May, 2011, Histogenics acquired Prochon BioTech.
ProChon Biotech names Dr. Jack Farr to Scientific Advisory Board
Study: BioCart™ System Shows Promise, Elisabeth Hofheinz, M.P.H., M.Ed.


Idera Pharmaceuticals, Inc.
(NGM: IDRA)
[Micro-Cap Biotech/Device]
Idera is focused on the discovery and development of novel therapeutics that modulate immune responses through Toll-like receptors (TLR) for the treatment of multiple diseases.
>>> Video Profile
Idera Pharmaceuticals Presents Preclinical Data on Novel Gene-Silencing Oligonucleotide Technology at TIDES 2011 Conference
Idera Pharmaceuticals to Present at the Noble Financial Capital Markets' Seventh Annual Equity Conference


Insituvue
(Private)
[Private Biotech/Device]
The company commercializes a device that gives medical professionals a better view during procedures, such as inserting catheters and IVs. The device is a hand-held ultrasound tool that displays a see-through image in the medical practitioners line of sight, at the patients skin surface.
Dr. Floyd Loop Joins Scientific Advisory Board
Insituvue Receives Federal Grant


Intellectual Ventures
(Private)
[Private Biotech/Device]
Intellectual Ventures is the global leader in the business of invention. They collaborate with leading inventors, partner with pioneering companies, and invest both expertise and capital in the development and monetization of inventions and patent portfolios. Their mission is to energize and streamline an invention economy that will drive innovation around the world.
Intellectual Ventures has issued a vote of confidence in Europe, says firm's Euro chief

California Institute of Technology and Intellectual Ventures Partnership to Fuel Innovation


IntelliCell BioSciences
(PNK: CWLC.PK)
[Micro-Cap Biotech/Device]
IntelliCell BioSciences Inc. is an emerging leader in regenerative medicine and the use of adipose derived stem cell processes and therapeutic treatments. IntelliCell has developed a pioneering system that allows doctors to treat patients in a number of clinically relevant areas. We are currently planning a series of clinical studies ranging from medical aesthetics, osteoarthritis, cartilage restoration, and more.
>>> Video Profile
CORRECTING and REPLACING IntelliCell BioSciences Signs Merger Agreement with Media Exchange Group



InTUUN Systems, LLC
(Private)
[Private Biotech/Device]
InTUUN is a leading health care information technology and services company focused on creating clinically integrated networks of medical practices, physician organizations and hospitals to enable collaborative patient care and measurable improvements in cost and quality across large patient populations.
InTUUN CHR v9.6 Achieves Complete EHR Certification
InTUUN Awarded Best Technology Start-Up of the Year


MacuCLEAR Inc.
(Private)
[Private Biotech/Device]
MacuCLEAR Inc. is a specialty clinical-stage pharmaceutical company focused on developing and commercializing novel solutions for vascular disorders of the eye. It's first target is Age Related Macular Degeneration, (AMD), the leading cause of blindness for people over 50 years of age, affecting 30 million people worldwide, representing a $5Billion market, for which there is currently no approved treatment for 90% who have this terrible disease. It is at the Phase II human clinical trials stage.
>>> Video Profile
Intellectual Ventures has issued a vote of confidence in Europe, says firm's Euro chief

California Institute of Technology and Intellectual Ventures Partnership to Fuel Innovation


MedicaSafe
(Private)
[Private Biotech/Device]
MedicaSafe creates innovative technologies for medication compliance and adherence. These solutions also address needs for regular patient assessment, tracking, and medication access management, enabling creation of comprehensive treatment management systems that reduce labor and costs while improving outcomes.


MEDomics
(Private)
[Private Biotech/Device]
MEDomics, LLC, a molecular diagnostic laboratory, provides support to physicians in delivering medicine based on analysis of the patient's genome. Its services include co- experimental design and wet bench, bioinformatics, post-bioinformatics interpretation, and manuscript co-preparation services.
Medomics Raises Funds to Grow its Sequencing-Based Tests for Mitochondrial Disease
MEDomics Mutation Expert Presents the Tarzan Model of Mutagenesis at the 2011 Plant and Animal Genome Conference


Monitor-it S.A.
(Private)
[Private Biotech/Device]
MONITOR-it S.A. develops diagnostic devices using the (patent protected) Pulse Transit Time as early CHF crisis indicator. The primary use is in home monitoring of chronic patients with congestive heart failure (CHF) in order to avoid acute (and hence expensive) hospitalizations.


NanoViricides, Inc.
(OTCBB: NNVC)
[Micro-Cap Biotech/Device]
The Company is a pre-clinical biotech company focused on an evolving $100B world-wide market. They are developing drugs aimed at the destruction of viruses in the body. The Company has drug candidates against nine different viruses: Ebola, Marburg, adenovirus and herpes simplex virus of the external eye, HIV, rabies, dengue and all influenza viruses. All of the drugs consist of a nanomicelle (a polymer-based 20nm lipophilic structure) that is attached to a ligand (receptor molecule).
>>> Video Profile
NanoViricides to Present Influenza Study Results at the TechConnect World 2011 Conference in Boston
Treatment with NanoViricides FluCide™ Drug Candidates Resulted in a 1000-fold Reduction of Viral Load in the Lungs of Animals Infected with Lethal Dose of Influenza Virus


NeoStem
(AMEX: NBS)
[Micro-Cap Biotech/Device]
NeoStem, Inc. is an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units: (i) U.S. adult stem cells, (ii) China adult stem cells, (iii) China pharmaceuticals.
>>> Video Profile
NeoStem's Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility
NeoStem to Present at 10th Annual Needham Healthcare Conference on Tuesday, April 5


NeuroWave Systems
(Private)
[Private Biotech/Device]
NeuroWave is a medical device manufacturer (ISO & FDA compliant) of innovative non-invasive brain monitors for clinical applications in Anesthesia, Critical Care, Neurology & Emergency Medicine. The flagship product is the CE Marked NeuroSENSE, the next generation brain monitor for safe & accurate delivery of anesthesia & sedation in Operating Rooms (ORs) and Intensive Care Units (ICUs). NeuroWave's mission is to develop, manufacture, and market monitoring products using advanced signal processing of brain waves (electroencephalogram - EEG) and other biosignals in order to improve patient outcome and quality of life.
NeuroWave to Develop a Portable Closed-Loop Anesthesia System (AutoTIVA™)
CareFusion to Distribute NeuroSENSE® Monitor in Scandinavia and Germany
NeuroWave Obtains 510(k) Clearance for NeuroFAST™ Monitoring System (NF-201)
NeuroWave announces the presentation of 3 Scientific Abstracts at the American Society of Anesthesiologists Annual Meeting


Northwest Biotherapeutics
(OTC: NWBO.OB)
[Micro-Cap Biotech/Device]
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer.
>>> Video Profile
"NORTHWEST BIOTHERAPEUTICS FURTHER EXPANDS ONGOING BRAIN CANCER TRIAL
Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
"


PearlDiver
(Private)
[Private Biotech/Device]
PearlDiver Technologies, Inc. is a life sciences information, data and research firm. PearlDiver's engineers and analysts aggregate, process and then organize existing databases of patient, reimbursement, claims and clinical data into products for manufacturers, hospitals, patients, insurance companies and others. PearlDiver maintains a patient record database that contains up to 500 million records.
>>> Video Profile
Extremities Device Market-Still Undefined!
Spinal Motion Preservation: Update and Outlook


Physicians Interactive Holding
(Private)
[Private Biotech/Device]
Physicians Interactive Holdings is the leading resource for healthcare information, medication samples and mobile decision support tools to medical professional everywhere. PIH use the full power of their network to bring clinicians and Life Sciences Companies together in ways that will change the practice and business of medicine, for the better. PIH was developed in 2008 with Physicians Interactive as its core company and has been actively expanding its capabilities with physicians and health care professionals.
>>> Video Profile
E-Detailing Trends
Man Vs. Machine


Phytoceuticals, Ltd.
(Private)
[Private Biotech/Device]
Phytoceuticals is a life science company that develops innovative medicines from natural product extracts. The Company's current focus is to develop first-in-class solutions for major indications in dermatology. Upon receiving product registration, Phytoceuticals aims at partnering with strong industry partners for product distribution in order to maximize the potential reach and revenue for the product. Phytoceuticals' lead product 1 PRIMARY WOUND DRESSING is an effective FIRST CHOICE product for the treatment of acute and chronic wounds.
>>> Video Profile
Phytoceuticals ltd. receives CE Mark for 1 PRIMARY WOUND DRESSING®

Phytoceuticals ltd. elects Stephen Rietiker, M.D., as Chairman of the Board


QR Pharma, Inc
(Private)
[Private Biotech/Device]
The company has two compounds in clinical development, both with disease modifying activities, e.g. they have the potential to stop the progression of the disease as well as symptomatic efficacy. QR Pharma, Inc is a specialty pharmaceutical company founded to develop novel drugs for the treatment of Alzheimer's Disease (AD).
QR Pharma to Present at BIO-Windhover Conference /Pharmaceutical Strategic Outlook 2011
Jeffrey Cummings, Rachelle Doody, Martin Farlow and Mary Sano to Form QR Pharma's Medical Advisory Board


Rubigo Therapeutics
(Private)
[Private Biotech/Device]
Rubigo Therapeutics is a development stage company focused on a combination product to deliver a FDA approved, now generic immune response modifying drug through a proprietary polymeric material that enables improved control and direction delivery of the therapeutic molecule.


Saluda Medical Pty Ltd
(Private)
[Private Biotech/Device]
Saluda Medical is a private company spun out of NICTA and is developing the next generation of implantable neuro-modulation systems based on technology licensed from NICTA for the treatment of chronic neuropathic pain.
>>> Video Profile
NICTA beams Graeme Clark Oration to regional universities
NICTA P2P network engine speeds into US and Europe


SEA Medical Systems, Inc.
(Private)
[Private Biotech/Device]
S.E.A. Medical Systems, Inc. is a private healthtech company pioneering smart products for safe manufacture, preparation, delivery and disposal of IV and liquid medications. The product systems consist of electronic monitors, disposable sensors and drug library software. They instantly detect drug, concentration and diluent to avoid errors that injure or kill patients, and improve management of intravenous medicine.
>>> Video Profile
S.E.A. Medical Systems, Inc. Featured at BayBio2011 in San Francisco on April 21, 2011


Small Bone Innovations
(Private)
[Private Biotech/Device]
Small Bone Innovations, Inc. offers a broad, clinically proven portfolio of products and technologies including the market leading S.T.A.R. total ankle replacement system. Today, SBi has facilities in New York, NY, Morrisville, PA, Bourg-en-Bresse, France, Donaueschingen, Germany, and Kuala Lumpur, Malaysia and distribution in more than 50 countries.
>>> Video Profile
Health Net Plan Members Gain Access to STAR Total Ankle Replacement System
SMALL BONE INNOVATIONS, INC. RECEIVES ACCREDITATION FROM JAPAN FOR ITS FACILITIES


SpectraScience
(.PK: SCIE)
[Micro-Cap Biotech/Device]
SpectraScience, Inc. focuses on developing the WavSTAT Optical Biopsy System (WavSTAT System), a minimally invasive spectroscopic system that optically scans tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue, without the need to remove tissue from the body.
>>> Video Profile
SpectraScience to Host Shareholder Update Call
SpectraScience Inc. Addresses Commencement of Trading on OTCQB


ThermoGenesis
(Nasdaq: KOOL)
[Micro-Cap Biotech/Device]
ThermoGenesis develops and manufactures innovative and enabling technologies that address Stem Cell Processing and Cryopreservation.
>>> Video Profile
ThermoGenesis Reports Third Quarter Fiscal 2011 Results; Major Progress Achieved in China & India
ThermoGenesis Announces China Customer Implements Cord Blood Products


Threshold Pharmaceuticals
(NASDAQ: THLD)
[Micro-Cap Biotech/Device]
Threshold is a biotechnology company focused on the discovery and development of therapeutics that selectively target the oxygen-deprived or "hypoxic" regions that are characteristic of solid tumors as well as hematologic cancers.
>>> Video Profile
Threshold Pharmaceuticals Presents Positive Preclinical Results at International Myeloma Workshop

Threshold Update Since Sudden Death of Its Chief Medical Officer; Samuel Saks, M.D., to Join the Company as Interim Chief Medical Officer


Wafergen Biosystems
(OTC: WGBS.OB)
[Micro-Cap Biotech/Device]
WaferGen Biosystems, Inc. is a leader in the development, manufacture, and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker identification and validation.
>>> Video Profile
WaferGen Announces Data Presentations from Newly Launched SmartChip Human microRNA Panel V2 at Scientific Conferences, including AACR
WaferGen Launches High-Throughput SmartChip Human MicroRNA Panel


Wound Management Technologies, Inc
(PINK: WNDM)
[Micro-Cap Biotech/Device]
Wound Management Technologies, Inc. (WNDM) is a rapidly growing provider of advanced biotech medical devices. Our lead product, CellerateRX, is a unique, patented activated collagen that addresses the expanding diabetes and greater wound care markets.
>>> Video Profile
WNDM Signs $1.5 M Multiyear Regional Distribution Agreement
WNDM Secures Additional International Sales ; $150K in New Orders for 2011


XDx Inc.
(Private)
[Private Biotech/Device]
XDx develops molecular diagnostics that translate an individual's immune status into clinically actionable information.
Anthem Blue Cross Has Determined AlloMap® Necessary for Heart Transplant Recipients
Studies Presented at 31st Annual ISHLT Meeting Expand Understanding of AlloMap®


ZABeCor Pharmaceuticals, LLC
(Private)
[Private Biotech/Device]
ZaBeCor Pharmaceuticals, LLC is a clinical stage biopharmaceutical company focused on the development of siRNA, antisense and other molecular technologies for the treatment of asthma, COPD, allergic rhinitis, arthritis and many other inflammatory disorders. ZaBeCor's lead product is Excellair™, targeted to the signaling protein Syk kinase. By targeting Syk kinase, Excellair™, inhibits an initial signaling step of inflammation, thereby preventing the release of multiple inflammatory mediators. Phase I data demonstrate a strong safety profile in patients with asthma and Phase II data demonstrate meaningful efficacy in patients with asthma.
>>> Video Profile
"ZaBeCor Pharmaceuticals Begins Phase II Clinical Trial In Asthma Patients Following Positive Phase I Results
ZaBeCor Pharmaceuticals Announces Formation of Biothorpe Pharmaceuticals
"




Presenting Companies from Past OneMedForums

SF Jan 2011 / NY June 2010 / SF Jan 2010

Presenting Company Benefits (PDF)